Skip to main content

Table 1 Characteristicsa of 818 patients with acute myeloid leukaemia (AML)

From: Longitudinal trajectory patterns of plasma albumin and C-reactive protein levels around diagnosis, relapse, bacteraemia, and death of acute myeloid leukaemia patients

Text Number (%)b
Females 373 (45.6)
Males 445 (54.4)
Age, years
 Range 15.2–95.6
 Median (interquartile range) 69.4 (59.3–76.8)
Charlson comorbidity index
 0 434 (53.1)
 1–2 270 (33.0)
  > 2 114 (13.9)
No. bacteraemic episodes
 0 410 (50.1)
 1 215 (26.3)
 2 93 (11.4)
 3 61 (7.5)
 4 20 (2.4)
 5–9 19 (2.3)
Microbiological isolates, first bacteraemic episode
 Mono-microbial Gram-positive 349 (42.7)
Staphylococcus aureus 27 (3.5)
  Coagulase-negative staphylococci 112 (14.3)
Streptococcus pneumoniae 12 (1.5)
  Streptococci, other 10 (1.3)
Enterococcus faecalis 134 (17.1)
  Other 54 (6.9)
 Mono-microbial Gram-negative 308 (37.7)
Escherichia coli 127 (16.2)
Klebsiella spp. 53 (6.8)
Pseudomonas aeruginosa 30 (3.8)
  Other 98 (12.5)
 Mono-microbial fungi 18 (2.3)
 Poly-microbial 107 (13.7)
Neutrophil granulocytes (10^9/L)
  < 0.5 182 (22.2)
 0.5–0.9 78 (9.5)
 1.0–1.4 44 (5.4)
  ≥ 1.5 215 (26.3)
 Not measured 299 (36.6)
Bone marrow biopsy blast percentage
 0–19 14 (1.7)c
 20–39 283 (34.6)
 40–59 182 (22.3)
 60–79 154 (18.8)
 80–100 132 (16.1)
 Not measured 53 (6.5)
Intended treatment at AML diagnosis  
 Curative chemotherapy 501 (61.3)
 Palliative chemotherapy 91 (11.1)
 Best supportive care 218 (26.7)
 Unknown 8 (1.0)
Vital status 1 y after the AML diagnosis date
 Deceased 439 (53.7)
 Alive 372 (45.5)
 Unknownd 7 (0.9)
Vital status 2–5 y after the AML diagnosis date
 Deceased 215 (57.8)e
 Alive 96 (25.8)e
 Unknownf 61 (17.5)e
  1. aOn date of AML diagnosis, except for no. bacteraemic episodes and vital status data
  2. bExcept for “Age, years”, cf. text
  3. cThese 14 patients had an extra-medullary AML location
  4. dLess than 1 year between diagnosis date and latest vital status date (24 November 2017) on which they were alive
  5. eDenominator is the 372 patients who were alive 1 year after the AML diagnosis date
  6. fLess than 5 years between diagnosis date and latest vital status date (24 November 2017) on which they were alive